Pharmacogenetics: From Bench to Byte-An Update of Guidelines

被引：766

作者：

Swen, J. J. ^{[1
]}

Nijenhuis, M. ^{[2
]}

de Boer, A. ^{[3
]}

Grandia, L. ^{[2
]}

Maitland-van der Zee, A. H. ^{[3
]}

Mulder, H. ^{[3
,4
]}

Rongen, G. A. P. J. M. ^{[5
,6
,7
]}

van Schaik, R. H. N. ^{[8
]}

Schalekamp, T. ^{[3
]}

Touw, D. J. ^{[9
]}

van der Weide, J. ^{[10
]}

Wilffert, B. ^{[11
]}

Deneer, V. H. M. ^{[12
]}

Guchelaar, H-J ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands

[2] KNMP, Div Drug Informat Ctr, The Hague, Netherlands

[3] Univ Utrecht, Fac Sci, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands

[4] Wilhelmina Hosp Assen, Dept Clin Pharm, Assen, Netherlands

[5] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol Toxicol, NL-6525 ED Nijmegen, Netherlands

[6] Radboud Univ Nijmegen, Med Ctr, Dept Gen Internal Med, NL-6525 ED Nijmegen, Netherlands

[7] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Evidence Based Practice, NL-6525 ED Nijmegen, Netherlands

[8] Erasmus Univ, Dept Clin Chem, Med Ctr, Rotterdam, Netherlands

[9] Cent Hosp Pharm, The Hague, Netherlands

[10] St Jansdal Hosp, Dept Clin Chem, Harderwijk, Netherlands

[11] Zorggrp Noorderbreedte, Dept Qual & Patient Safety, Leeuwarden, Netherlands

[12] St Antonius Hosp, Dept Clin Pharm, Nieuwegein, Netherlands

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 89卷 / 05期

关键词：

WARFARIN; GENOTYPE; GENE;

D O I：

10.1038/clpt.2011.34

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch Association for the Advancement of Pharmacy established the Pharmacogenetics Working Group with the objective of developing pharmacogenetics-based therapeutic (dose) recommendations. After systematic review of the literature, recommendations were developed for 53 drugs associated with genes coding for CYP2D6, CYP2C19, CYP2C9, thiopurine-S-methyltransferase (TPMT), dihydropyrimidine dehydrogenase (DPD), vitamin K epoxide reductase (VKORC1), uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), HLA-B44, HLA-B*5701, CYP3A5, and factor V Leiden (FVL).

引用

页码：662 / 673

页数：12

共 14 条

[1]

[Anonymous], 2013, Table of Pharmacogenomic Biomarkers in Drug Labels

[2]

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

[3]

Clinically Available Pharmacogenomics Tests [J].

Flockhart, D. A. ;

Skaar, T. ;

Berlin, D. S. ;

Klein, T. E. ;

Nguyen, A. T. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (01) :109-113

[4]

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:: a first step towards subpopulation-specific dosages [J].

Kirchheiner, J ;

Brosen, K ;

Dahl, ML ;

Gram, LF ;

Kasper, S ;

Roots, I ;

Sjöqvist, F ;

Spina, E ;

Brockmöller, J .

ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (03) :173-192

[5]

Klein TE, 2009, NEW ENGL J MED, V360, P753

[6]

Identification of the gene for vitamin K epoxide reductase [J].

Li, T ;

Chang, CY ;

Jin, DY ;

Lin, PJ ;

Khvorova, A ;

Stafford, DW .

NATURE, 2004, 427 (6974) :541-544

[7]

HLA-B*5701 screening for hypersensitivity to abacavir [J].

Mallal, Simon ;

Phillips, Elizabeth ;

Carosi, Giampiero ;

Molina, Jean-Michel ;

Workman, Cassy ;

Tomazic, Janez ;

Jaegel-Guedes, Eva ;

Rugina, Sorin ;

Kozyrev, Oleg ;

Cid, Juan Flores ;

Hay, Phillip ;

Nolan, David ;

Hughes, Sara ;

Hughes, Arlene ;

Ryan, Susanna ;

Fitch, Nicholas ;

Thorborn, Daren ;

Benbow, Alastair .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :568-579

[8]

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose [J].

Rieder, MJ ;

Reiner, AP ;

Gage, BF ;

Nickerson, DA ;

Eby, CS ;

McLeod, HL ;

Blough, DK ;

Thummel, KE ;

Veenstra, DL ;

Rettie, AE .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2285-2293

[9]

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 [J].

Rost, S ;

Fregin, A ;

Ivaskevicius, V ;

Conzelmann, E ;

Hörtnagel, K ;

Pelz, HJ ;

Lappegard, K ;

Seifried, E ;

Scharrer, I ;

Tuddenham, EGD ;

Müller, CR ;

Strom, TM ;

Oldenburg, J .

NATURE, 2004, 427 (6974) :537-541

[10]

Pharmacogenetics: From bench to byte [J].

Swen, J. J. ;

Wilting, I. ;

de Goede, A. L. ;

Grandia, L. ;

Mulder, H. ;

Touw, D. J. ;

de Boer, A. ;

Conemans, J. M. H. ;

Egberts, T. C. G. ;

Klungel, O. H. ;

Koopmans, R. ;

van der Weide, J. ;

Wilffert, B. ;

Guchelaar, H-J ;

Deneer, V. H. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (05) :781-787

← 1 2 →